Format

Send to

Choose Destination
Lancet Oncol. 2015 Mar;16(3):e101. doi: 10.1016/S1470-2045(14)71220-3.

Japanese regulatory authority's perspective on biosimilars.

Author information

1
Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; Division of Genetic Therapeutics, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan. Electronic address: sunagai-tky@umin.ac.jp.
2
Office of Standards and Guidelines Development, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
3
Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
PMID:
25752552
DOI:
10.1016/S1470-2045(14)71220-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center